Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Intragenic antagonistic roles of protein and circRNA in tumorigenesis.

Guarnerio J, Zhang Y, Cheloni G, Panella R, Mae Katon J, Simpson M, Matsumoto A, Papa A, Loretelli C, Petri A, Kauppinen S, Garbutt C, Petur Nielsen G, Deshpande V, Castillo-Martin M, Cordon-Cardo C, Dimitrios S, Clohessy JG, Batish M, Pandolfi PP.

Cell Res. 2019 Aug;29(8):628-640. doi: 10.1038/s41422-019-0192-1. Epub 2019 Jun 17.

PMID:
31209250
2.

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.

Lee YR, Chen M, Lee JD, Zhang J, Lin SY, Fu TM, Chen H, Ishikawa T, Chiang SY, Katon J, Zhang Y, Shulga YV, Bester AC, Fung J, Monteleone E, Wan L, Shen C, Hsu CH, Papa A, Clohessy JG, Teruya-Feldstein J, Jain S, Wu H, Matesic L, Chen RH, Wei W, Pandolfi PP.

Science. 2019 May 17;364(6441). pii: eaau0159. doi: 10.1126/science.aau0159.

PMID:
31097636
3.

Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.

Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee JD, Mendez L, Menon AV, Aster JC, Lane AA, Stone RM, Galinsky I, Zamora JC, Lo-Coco F, Bhasin MK, Avigan D, Longo L, Clohessy JG, Pandolfi PP.

Cell Res. 2019 Jun;29(6):446-459. doi: 10.1038/s41422-019-0162-7. Epub 2019 Apr 25.

PMID:
31024166
4.

The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care.

Clohessy JG, Pandolfi PP.

Front Oncol. 2018 Aug 28;8:340. doi: 10.3389/fonc.2018.00340. eCollection 2018.

5.

An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance.

Bester AC, Lee JD, Chavez A, Lee YR, Nachmani D, Vora S, Victor J, Sauvageau M, Monteleone E, Rinn JL, Provero P, Church GM, Clohessy JG, Pandolfi PP.

Cell. 2018 Apr 19;173(3):649-664.e20. doi: 10.1016/j.cell.2018.03.052.

6.

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.

Ali A, Levantini E, Teo JT, Goggi J, Clohessy JG, Wu CS, Chen L, Yang H, Krishnan I, Kocher O, Zhang J, Soo RA, Bhakoo K, Chin TM, Tenen DG.

EMBO Mol Med. 2018 Mar;10(3). pii: e8313. doi: 10.15252/emmm.201708313.

7.

An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, Liu XS, Lee YR, Fung J, Katon JM, Menon AV, Webster KA, Ng C, Palumbieri MD, Diolombi MS, Breitkopf SB, Teruya-Feldstein J, Signoretti S, Bronson RT, Asara JM, Castillo-Martin M, Cordon-Cardo C, Pandolfi PP.

Nat Genet. 2018 Feb;50(2):206-218. doi: 10.1038/s41588-017-0027-2. Epub 2018 Jan 15.

PMID:
29335545
8.

Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.

Chen M, Wan L, Zhang J, Zhang J, Mendez L, Clohessy JG, Berry K, Victor J, Yin Q, Zhu Y, Wei W, Pandolfi PP.

Nat Commun. 2018 Jan 15;9(1):159. doi: 10.1038/s41467-017-02272-y.

9.

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.

Bezzi M, Seitzer N, Ishikawa T, Reschke M, Chen M, Wang G, Mitchell C, Ng C, Katon J, Lunardi A, Signoretti S, Clohessy JG, Zhang J, Pandolfi PP.

Nat Med. 2018 Feb;24(2):165-175. doi: 10.1038/nm.4463. Epub 2018 Jan 8.

PMID:
29309058
10.

Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.

van de Ven AL, Tangutoori S, Baldwin P, Qiao J, Gharagouzloo C, Seitzer N, Clohessy JG, Makrigiorgos GM, Cormack R, Pandolfi PP, Sridhar S.

Mol Cancer Ther. 2017 Jul;16(7):1279-1289. doi: 10.1158/1535-7163.MCT-16-0740. Epub 2017 May 12.

11.

SPAR, a lncRNA encoded mTORC1 inhibitor.

Matsumoto A, Clohessy JG, Pandolfi PP.

Cell Cycle. 2017 May 3;16(9):815-816. doi: 10.1080/15384101.2017.1304735. Epub 2017 Mar 20. No abstract available.

12.

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC.

Cancer Discov. 2017 Jul;7(7):750-765. doi: 10.1158/2159-8290.CD-16-0778. Epub 2017 Mar 8.

13.

mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide.

Matsumoto A, Pasut A, Matsumoto M, Yamashita R, Fung J, Monteleone E, Saghatelian A, Nakayama KI, Clohessy JG, Pandolfi PP.

Nature. 2017 Jan 12;541(7636):228-232. doi: 10.1038/nature21034. Epub 2016 Dec 26.

PMID:
28024296
14.

The pleiotropic role of non-coding genes in development and cancer.

Pasut A, Matsumoto A, Clohessy JG, Pandolfi PP.

Curr Opin Cell Biol. 2016 Dec;43:104-113. doi: 10.1016/j.ceb.2016.10.005. Epub 2016 Nov 16. Review.

15.

Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma.

Tan JL, Fogley RD, Flynn RA, Ablain J, Yang S, Saint-André V, Fan ZP, Do BT, Laga AC, Fujinaga K, Santoriello C, Greer CB, Kim YJ, Clohessy JG, Bothmer A, Pandell N, Avagyan S, Brogie JE, van Rooijen E, Hagedorn EJ, Shyh-Chang N, White RM, Price DH, Pandolfi PP, Peterlin BM, Zhou Y, Kim TH, Asara JM, Chang HY, Young RA, Zon LI.

Mol Cell. 2016 Apr 7;62(1):34-46. doi: 10.1016/j.molcel.2016.03.013.

16.

Mouse hospital and co-clinical trial project--from bench to bedside.

Clohessy JG, Pandolfi PP.

Nat Rev Clin Oncol. 2015 Aug;12(8):491-8. doi: 10.1038/nrclinonc.2015.62. Epub 2015 Apr 21. Review. Erratum in: Nat Rev Clin Oncol. 2015 Aug;12(8):499.

PMID:
25895610
17.

In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Li Chew C, Lunardi A, Gulluni F, Ruan DT, Chen M, Salmena L, Nishino M, Papa A, Ng C, Fung J, Clohessy JG, Sasaki J, Sasaki T, Bronson RT, Hirsch E, Pandolfi PP.

Cancer Discov. 2015 Jul;5(7):740-51. doi: 10.1158/2159-8290.CD-14-1347. Epub 2015 Apr 16.

18.

Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.

González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP.

Cancer Discov. 2014 Aug;4(8):896-904. doi: 10.1158/2159-8290.CD-13-0230. Epub 2014 May 27.

19.

Role of aberrant PI3K pathway activation in gallbladder tumorigenesis.

Lunardi A, Webster KA, Papa A, Padmani B, Clohessy JG, Bronson RT, Pandolfi PP.

Oncotarget. 2014 Feb 28;5(4):894-900.

20.

Of model pets and cancer models: an introduction to mouse models of cancer.

Lunardi A, Nardella C, Clohessy JG, Pandolfi PP.

Cold Spring Harb Protoc. 2014 Jan 1;2014(1):17-31. doi: 10.1101/pdb.top069757.

PMID:
24371312
21.

NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.

Rau R, Magoon D, Greenblatt S, Li L, Annesley C, Duffield AS, Huso D, McIntyre E, Clohessy JG, Reschke M, Pandolfi PP, Small D, Brown P.

Exp Hematol. 2014 Feb;42(2):101-13.e5. doi: 10.1016/j.exphem.2013.10.005. Epub 2013 Oct 29.

22.

Infrastructure needs for translational integration of mouse and human trials.

Clohessy JG, de Stanchina E.

Cold Spring Harb Protoc. 2013 Dec 1;2013(12):1109-14. doi: 10.1101/pdb.top078782.

PMID:
24173312
23.

Characterization and analysis of the composition and dynamics of the mammalian riboproteome.

Reschke M, Clohessy JG, Seitzer N, Goldstein DP, Breitkopf SB, Schmolze DB, Ala U, Asara JM, Beck AH, Pandolfi PP.

Cell Rep. 2013 Sep 26;4(6):1276-87. doi: 10.1016/j.celrep.2013.08.014. Epub 2013 Sep 19.

24.

The RNA binding protein ESRP1 fine-tunes the expression of pluripotency-related factors in mouse embryonic stem cells.

Fagoonee S, Bearzi C, Di Cunto F, Clohessy JG, Rizzi R, Reschke M, Tolosano E, Provero P, Pandolfi PP, Silengo L, Altruda F.

PLoS One. 2013 Aug 27;8(8):e72300. doi: 10.1371/journal.pone.0072300. eCollection 2013.

25.

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.

Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP.

Nat Genet. 2013 Jul;45(7):747-55. doi: 10.1038/ng.2650. Epub 2013 Jun 2.

26.

Found in translation of mTOR signaling.

Clohessy JG, Reschke M, Pandolfi PP.

Cell Res. 2012 Sep;22(9):1315-8. doi: 10.1038/cr.2012.85. Epub 2012 May 29.

27.

Pro-senescence therapy for cancer treatment.

Nardella C, Clohessy JG, Alimonti A, Pandolfi PP.

Nat Rev Cancer. 2011 Jun 24;11(7):503-11. doi: 10.1038/nrc3057. Review.

PMID:
21701512
28.

Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.

Nardella C, Lunardi A, Fedele G, Clohessy JG, Alimonti A, Kozma SC, Thomas G, Loda M, Pandolfi PP.

Cancer Res. 2011 May 15;71(10):3669-75. doi: 10.1158/0008-5472.CAN-10-3962. Epub 2011 Mar 28.

29.

Subtle variations in Pten dose determine cancer susceptibility.

Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, Richardson AL, Zhang J, Pandolfi PP.

Nat Genet. 2010 May;42(5):454-8. doi: 10.1038/ng.556. Epub 2010 Apr 18.

30.

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.

Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, Rosivatz E, Woscholski R, Cognetti F, Scher HI, Pandolfi PP.

J Clin Invest. 2010 Mar;120(3):681-93. doi: 10.1172/JCI40535. Epub 2010 Feb 8.

31.

The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model.

Cheng K, Sportoletti P, Ito K, Clohessy JG, Teruya-Feldstein J, Kutok JL, Pandolfi PP.

Blood. 2010 Apr 22;115(16):3341-5. doi: 10.1182/blood-2009-03-208587. Epub 2009 Aug 7.

32.

beta-tting on p63 as a metastatic suppressor.

Clohessy JG, Pandolfi PP.

Cell. 2009 Apr 3;137(1):28-30. doi: 10.1016/j.cell.2009.03.028.

33.

Differential requirement of mTOR in postmitotic tissues and tumorigenesis.

Nardella C, Carracedo A, Alimonti A, Hobbs RM, Clohessy JG, Chen Z, Egia A, Fornari A, Fiorentino M, Loda M, Kozma SC, Thomas G, Cordon-Cardo C, Pandolfi PP.

Sci Signal. 2009 Jan 27;2(55):ra2. doi: 10.1126/scisignal.2000189.

34.

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.

Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, Teruya-Feldstein J, Pandolfi PP.

Blood. 2008 Apr 1;111(7):3859-62. doi: 10.1182/blood-2007-06-098251. Epub 2008 Jan 22.

35.

The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.

Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P, Pandolfi PP.

Oncogene. 2007 Nov 22;26(53):7391-400. Epub 2007 Jun 4.

PMID:
17546053
36.

Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis.

Clohessy JG, Zhuang J, de Boer J, Gil-Gómez G, Brady HJ.

J Biol Chem. 2006 Mar 3;281(9):5750-9. Epub 2005 Dec 27.

37.

Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells.

Clohessy JG, Zhuang J, Brady HJ.

Br J Haematol. 2004 Jun;125(5):655-65.

PMID:
15147382

Supplemental Content

Loading ...
Support Center